Do family health conversations impact patients with glioblastoma multiforme and their family members?

Inge Faarup, Jørgen T. Lauridsen*, Karin Lütgen, Anni Nørregaard, Frantz Rom Poulsen, Birte Østergaard

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Aims and objectives: To assess the impact of family health conversations (FamHC) as a supplement to conventional care on health-related quality of life (HRQoL), family functioning (FFSS) and family hardiness or resilience (FHI) 4 and 14 weeks postoperatively among patients with glioblastoma multiforme and their family members. Background: There is a lack of knowledge about the efficiency of FamHC among families experiencing glioblastoma multiforme. Design: A quasi-experimental pre- and post-test design adhering to the STROBE (Strengthening the reporting of observational studies in epidemiology) guidelines for case–control studies. Patients and family members were included consecutively in the pretest period from November 2013–December 2014 for the control group (offered traditional care only), and in the post-test period from January 2015–December 2015 for the intervention group (offered traditional care and FamHC). For both groups, 4 and 14 weeks postoperative measurement were obtained. Methods: Differences in outcomes were assessed using a difference-in-difference regression analysis approach measuring difference across pre and post groups and across 4 and 14 weeks measurements. Results: The study does not reveal significant effects of FamHC (all p-values larger than 0.05) as measured by the three instruments WHOQOL-BREF, FFSS and FHI. Conclusions: The present study was not able to show significant effects of FamHC. However, it cannot be left out that the intervention might be helpful and supportive at a later state of the illness trajectory. Relevance for clinical practice: The study adds to the growing evidence-based knowledge on FamHC by questioning their potential use in different cultural contexts among families experiencing critical illness. Oncological nurses need to adapt this information to support their daily care for the patients and their close relatives. For future studies, it is recommended that the families themselves choose when the conversations should take place during the course of the illness.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Nursing
Vol/bind28
Udgave nummer9-10
Sider (fra-til)1695-1707
ISSN0962-1067
DOI
StatusUdgivet - 1. maj 2019

Fingeraftryk

Family Health
Glioblastoma
Critical Illness
Epidemiology
Nurses
Regression Analysis
Quality of Life
Guidelines
Control Groups

Citer dette

@article{ae22b9512fa54ee8b5416fa5cbf39848,
title = "Do family health conversations impact patients with glioblastoma multiforme and their family members?",
abstract = "Aims and objectives: To assess the impact of family health conversations (FamHC) as a supplement to conventional care on health-related quality of life (HRQoL), family functioning (FFSS) and family hardiness or resilience (FHI) 4 and 14 weeks postoperatively among patients with glioblastoma multiforme and their family members. Background: There is a lack of knowledge about the efficiency of FamHC among families experiencing glioblastoma multiforme. Design: A quasi-experimental pre- and post-test design adhering to the STROBE (Strengthening the reporting of observational studies in epidemiology) guidelines for case–control studies. Patients and family members were included consecutively in the pretest period from November 2013–December 2014 for the control group (offered traditional care only), and in the post-test period from January 2015–December 2015 for the intervention group (offered traditional care and FamHC). For both groups, 4 and 14 weeks postoperative measurement were obtained. Methods: Differences in outcomes were assessed using a difference-in-difference regression analysis approach measuring difference across pre and post groups and across 4 and 14 weeks measurements. Results: The study does not reveal significant effects of FamHC (all p-values larger than 0.05) as measured by the three instruments WHOQOL-BREF, FFSS and FHI. Conclusions: The present study was not able to show significant effects of FamHC. However, it cannot be left out that the intervention might be helpful and supportive at a later state of the illness trajectory. Relevance for clinical practice: The study adds to the growing evidence-based knowledge on FamHC by questioning their potential use in different cultural contexts among families experiencing critical illness. Oncological nurses need to adapt this information to support their daily care for the patients and their close relatives. For future studies, it is recommended that the families themselves choose when the conversations should take place during the course of the illness.",
author = "Inge Faarup and Lauridsen, {J{\o}rgen T.} and Karin L{\"u}tgen and Anni N{\o}rregaard and Poulsen, {Frantz Rom} and Birte {\O}stergaard",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/jocn.14777",
language = "English",
volume = "28",
pages = "1695--1707",
journal = "Journal of Clinical Nursing",
issn = "0962-1067",
publisher = "Wiley-Blackwell",
number = "9-10",

}

Do family health conversations impact patients with glioblastoma multiforme and their family members? / Faarup, Inge; Lauridsen, Jørgen T.; Lütgen, Karin; Nørregaard, Anni; Poulsen, Frantz Rom; Østergaard, Birte.

I: Journal of Clinical Nursing, Bind 28, Nr. 9-10, 01.05.2019, s. 1695-1707.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Do family health conversations impact patients with glioblastoma multiforme and their family members?

AU - Faarup, Inge

AU - Lauridsen, Jørgen T.

AU - Lütgen, Karin

AU - Nørregaard, Anni

AU - Poulsen, Frantz Rom

AU - Østergaard, Birte

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Aims and objectives: To assess the impact of family health conversations (FamHC) as a supplement to conventional care on health-related quality of life (HRQoL), family functioning (FFSS) and family hardiness or resilience (FHI) 4 and 14 weeks postoperatively among patients with glioblastoma multiforme and their family members. Background: There is a lack of knowledge about the efficiency of FamHC among families experiencing glioblastoma multiforme. Design: A quasi-experimental pre- and post-test design adhering to the STROBE (Strengthening the reporting of observational studies in epidemiology) guidelines for case–control studies. Patients and family members were included consecutively in the pretest period from November 2013–December 2014 for the control group (offered traditional care only), and in the post-test period from January 2015–December 2015 for the intervention group (offered traditional care and FamHC). For both groups, 4 and 14 weeks postoperative measurement were obtained. Methods: Differences in outcomes were assessed using a difference-in-difference regression analysis approach measuring difference across pre and post groups and across 4 and 14 weeks measurements. Results: The study does not reveal significant effects of FamHC (all p-values larger than 0.05) as measured by the three instruments WHOQOL-BREF, FFSS and FHI. Conclusions: The present study was not able to show significant effects of FamHC. However, it cannot be left out that the intervention might be helpful and supportive at a later state of the illness trajectory. Relevance for clinical practice: The study adds to the growing evidence-based knowledge on FamHC by questioning their potential use in different cultural contexts among families experiencing critical illness. Oncological nurses need to adapt this information to support their daily care for the patients and their close relatives. For future studies, it is recommended that the families themselves choose when the conversations should take place during the course of the illness.

AB - Aims and objectives: To assess the impact of family health conversations (FamHC) as a supplement to conventional care on health-related quality of life (HRQoL), family functioning (FFSS) and family hardiness or resilience (FHI) 4 and 14 weeks postoperatively among patients with glioblastoma multiforme and their family members. Background: There is a lack of knowledge about the efficiency of FamHC among families experiencing glioblastoma multiforme. Design: A quasi-experimental pre- and post-test design adhering to the STROBE (Strengthening the reporting of observational studies in epidemiology) guidelines for case–control studies. Patients and family members were included consecutively in the pretest period from November 2013–December 2014 for the control group (offered traditional care only), and in the post-test period from January 2015–December 2015 for the intervention group (offered traditional care and FamHC). For both groups, 4 and 14 weeks postoperative measurement were obtained. Methods: Differences in outcomes were assessed using a difference-in-difference regression analysis approach measuring difference across pre and post groups and across 4 and 14 weeks measurements. Results: The study does not reveal significant effects of FamHC (all p-values larger than 0.05) as measured by the three instruments WHOQOL-BREF, FFSS and FHI. Conclusions: The present study was not able to show significant effects of FamHC. However, it cannot be left out that the intervention might be helpful and supportive at a later state of the illness trajectory. Relevance for clinical practice: The study adds to the growing evidence-based knowledge on FamHC by questioning their potential use in different cultural contexts among families experiencing critical illness. Oncological nurses need to adapt this information to support their daily care for the patients and their close relatives. For future studies, it is recommended that the families themselves choose when the conversations should take place during the course of the illness.

U2 - 10.1111/jocn.14777

DO - 10.1111/jocn.14777

M3 - Journal article

VL - 28

SP - 1695

EP - 1707

JO - Journal of Clinical Nursing

JF - Journal of Clinical Nursing

SN - 0962-1067

IS - 9-10

ER -